Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an announcement.
Prescient Therapeutics Limited announced a change in the director’s interest, with Melanie Farris acquiring 250,000 fully paid ordinary shares through an on-market trade. This transaction reflects a significant personal investment by a key company leader, potentially indicating confidence in the company’s future prospects and strategic direction.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company specializes in targeted and personalized medicine, aiming to improve treatment outcomes for cancer patients.
YTD Price Performance: -8.00%
Average Trading Volume: 610,533
Technical Sentiment Signal: Hold
Current Market Cap: A$37.04M
Learn more about PTX stock on TipRanks’ Stock Analysis page.